Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Lys) derived from bronchial tissue — one of the original tissue-specific peptides developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. As part of the Khavinson peptide bioregulator series, Bronchogen operates through epigenetic mechanisms to restore and maintain the gene expression patterns of bronchial epithelial cells that degrade with age, environmental damage, and chronic inflammation.

The bronchial epithelium is one of the most environmentally stressed tissues in the body — continuously exposed to inhaled pathogens, particulates, pollutants, and oxidative stress. This chronic exposure accelerates epigenetic silencing of protective genes: those encoding mucociliary clearance proteins, tight junction maintenance, anti-inflammatory cytokine modulators, and cellular repair enzymes. Bronchogen's tetrapeptide sequence penetrates bronchial epithelial cell nuclei and binds to histone-DNA complexes, specifically activating transcription of these silenced bronchial tissue genes.

Research from the Khavinson group has demonstrated that Bronchogen stimulates proliferation of bronchial epithelial cells, increases expression of respiratory mucosa-specific proteins, and reduces markers of chronic bronchial inflammation. In aged animal models, Bronchogen treatment resulted in measurable improvements in respiratory tract histology — with more intact epithelial architecture, improved mucociliary function, and reduced inflammatory cell infiltration compared to controls. These structural improvements translate to functional outcomes: improved respiratory efficiency and reduced susceptibility to respiratory infections.

In human clinical work, Bronchogen has been studied in aging populations with chronic respiratory dysfunction, patients with chronic bronchitis, and elderly individuals experiencing age-related respiratory decline. Outcomes include improvements in spirometric parameters (FEV1, FVC), reduced frequency and severity of respiratory infections, improved mucociliary clearance assessed by mucociliary transport rate, and subjective improvements in breathing capacity. The peptide's mechanism — tissue-specific epigenetic activation rather than direct anti-inflammatory drug action — means benefits accumulate over repeat courses rather than requiring continuous administration.

Bronchogen is particularly relevant for: smokers or ex-smokers with bronchial epithelial damage, individuals with chronic low-grade airway inflammation, aging populations experiencing progressive respiratory decline, and those in high-pollution environments with accelerated bronchial aging. The tissue-specific mechanism means Bronchogen acts directly on the affected tissue type rather than producing systemic immunosuppression.

Administration is typically intranasal or via sublingual absorption at 1–2mg/day for 10 consecutive days. The short tetrapeptide structure allows mucosal absorption without requiring injection, though subcutaneous administration is also used. Courses are repeated 2–4 times annually. The combination with Chonluten (lung mucosa bioregulator) provides complementary coverage of both bronchial epithelium and deeper pulmonary mucosa, addressing respiratory aging at multiple tissue levels simultaneously.